Medivation Announces Poster Presentations at AACR Annual Meeting 2012
Enzalutamide Designated Generic Name for MDV3100
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 -- Medivation, Inc. (NASDAQ: MDVN) today announced that the company will present data on enzalutamide (formerly MDV3100) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL on April 2, 2012.
Details are as follows:
(Poster #LB-109): MDV3100, an Androgen Receptor Signaling Inhibitor, Inhibits Tumor Growth in Breast Cancer Preclinical Models Regardless of Estrogen Receptor Status
Monday, April 2, 2012 from 8:00a.m. to noon
Location: McCormick Place West (Hall F), Poster Section 39
(Poster #2696): Modulation of Intracrine Androgen Signaling in Bone Metastatic Castrate Resistant Prostate Cancer (bmCRPC) by MDV3100
Monday, April 2, 2012 from 1:00-5:00p.m.
Location: McCormick Place West (Hall F), Poster Section 27
Medivation also announced that the United States Adopted Names Council has adopted enzalutamide as the generic name for MDV3100, the investigational compound currently in Phase 3 development to treat advanced prostate cancer.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug enzalutamide (formerly MDV3100) in Phase 3 development to treat advanced prostate cancer. For more information, please visit us at .
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.03.2012 - 05:00 Uhr
Sprache: Deutsch
News-ID 1098298
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 114 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medivation Announces Poster Presentations at AACR Annual Meeting 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
Medivation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
